Session » Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

Date: Saturday, November 12, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 0479

A Prospective Study Evaluating the Utility of Ultrasound in Monitoring Newly-Diagnosed GCA

1:00PM-3:00PM: Abstract Number: 0487

A Systematic Literature Review to Generate Descriptors for the Development of New Response Criteria in Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0467

All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study

1:00PM-3:00PM: Abstract Number: 0490

Analysis of Emergency Department Visits by Patients with Giant Cell Arteritis: A National Population-based Study

1:00PM-3:00PM: Abstract Number: 0485

Assessing the Effectiveness of Tocilizumab in Newly Diagnosed Giant Cell Arteritis versus Refractory/recurrent Giant Cell Arteritis in Clinical Practice

1:00PM-3:00PM: Abstract Number: 0466

Assessment of Probability Scores to Predict Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0460

Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial

1:00PM-3:00PM: Abstract Number: 0477

Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis?

1:00PM-3:00PM: Abstract Number: 0497

Classification Criteria and Existing Pre-Test Probability Stratification Tools Perform Poorly in Diagnosing Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0473

Comprehensive Assessment of Cranial and Orbital Vasculature on MRI in Patients with Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0488

Discrepancies in Temporal Artery Biopsy Positivity Rate Among White and Black Patients Suspected of Having Giant Cell Arteritis: Experience from a Tertiary Academic Medical Center

1:00PM-3:00PM: Abstract Number: 0484

Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis

1:00PM-3:00PM: Abstract Number: 0469

Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0486

Gene Expression Profile of Temporal Artery Tissue and Whole Blood in Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0489

Giant Cell Arteritis Phenotypes and Diagnosis of Aortitis Among 1852 Patients Before and After 2016 Across 10 French Referral Centers

1:00PM-3:00PM: Abstract Number: 0496

Giant Cell Arteritis Relapse Risk – Could the Extent of Vessel Involvement on Temporal and Axillary Arteries Ultrasound Be a Prognostic Marker?

1:00PM-3:00PM: Abstract Number: 0483

Giant Cell Arteritis: Physical Examination of the Superficial Temporal Arteries Can Predict Temporal Artery Biopsy Result

1:00PM-3:00PM: Abstract Number: 0481

Glucocorticoid-related Adverse Events in Giant Cell Arteritis: Application of the Glucocorticoid Toxicity Index in a Monocentric Cohort of 140 Patients

1:00PM-3:00PM: Abstract Number: 0462

Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years

1:00PM-3:00PM: Abstract Number: 0464

JAKINIB in Refractory Giant Cell Arteritis. National Multicenter Study of 15 Cases and Literature Review

1:00PM-3:00PM: Abstract Number: 0470

Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial

1:00PM-3:00PM: Abstract Number: 0492

Longitudinal Tends of Hospitalizations for Giant Cell Arteritis: A 21-year Longitudinal National Population-based Study

1:00PM-3:00PM: Abstract Number: 0491

Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis

1:00PM-3:00PM: Abstract Number: 0493

MRI Is Superior to Ultrasound of Supraaortic Arteries in Detecting Giant Cell Arteritis – Experience of a Single Center

1:00PM-3:00PM: Abstract Number: 0476

Permanent Vision Loss in Giant Cell Arteritis: Why the Incidence Remains High

1:00PM-3:00PM: Abstract Number: 0458

Predictive Models for Thromboembolic Events in Giant Cell Arteritis: A US Veterans Health Administration Population-Based Study

1:00PM-3:00PM: Abstract Number: 0494

Risk for Visual Loss in Patients with Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0482

Role of miR-146a and miR-146b in Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0495

Seasonal Variation in the Incidence of GCA in the UK and Ireland

1:00PM-3:00PM: Abstract Number: 0471

Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)

1:00PM-3:00PM: Abstract Number: 0478

Sonographic Prevalence of Subclinical GCA in Newly Diagnosed PMR

1:00PM-3:00PM: Abstract Number: 0472

The Common Carotid Artery in the Ultrasound Evaluation of Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0461

The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0459

The Use of Intravenous Methylprednisolone in Patients with Giant Cell Arteritis: A Population-Based Study

1:00PM-3:00PM: Abstract Number: 0465

Tocilizumab in Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: Multicentric Observational Comparative Study

1:00PM-3:00PM: Abstract Number: 0480

Treatment of Giant Cell Arteritis Patients with Ultra-short Glucocorticoids and Tocilizumab: Role of Imaging in a Prospective Study

1:00PM-3:00PM: Abstract Number: 0468

Ultrasound Wall Thickness in the Differential Diagnosis of Atherosclerosis and Large Vessel Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0474

Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients

1:00PM-3:00PM: Abstract Number: 0463

Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center

1:00PM-3:00PM: Abstract Number: 0475

Whole-country and Regional Incidences of Giant Cell Arteritis in French Continental and Overseas Territories: A Nationwide Database Analysis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].